Talha Munir

24PUBLICATIONS

125CO-AUTHORS

Haematological tumoursPredictive and prognostic markersLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (24)

Sort by Publication Date:

|Jun 17, 2026

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

|Jun 11, 2026

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

|Mar 31, 2026

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Richard R Furman, William G Wierda, Piers Em Patten

|Mar 30, 2026

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

David J Allsup, David A Cairns, E Faye Samy

|Jan 26, 2026

An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.

Mazyar Shadman, Constantine S Tam, Danielle M Brander

|Jan 16, 2026

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

Pageof 4

Frequent Collaborators

Toby A Eyre

Paolo Ghia

Constantine S Tam

Morag Griffin

Piers Em Patten

Jennifer R Brown

Ian W Flinn

Ewa Lech-Maranda

Shuo Ma

Chan Y Cheah

Frequent Collaborators

Toby A Eyre

Paolo Ghia

Constantine S Tam

Morag Griffin